Tokyo, July 30, 2021

## 2021 Second Quarter Results

## Year-to-Date Highlights (vs. 2020)

- Revenue increased $11.1 \%$ to JPY 1,144.5 billion.
- Adjusted operating profit at constant currency increased $26.9 \%$ to JPY 365.1 billion.
- On a reported basis, adjusted operating profit increased $24.5 \%$ to JPY 358.2 billion.
- Operating profit increased 27.8\% to JPY 322.1 billion.
- Profit attributable to owners of the parent company increased $30.5 \%$ to JPY 225.2 billion.
- The Company announced to offer an interim dividend of JPY 65 as initially planned.


## FY2021 Forecasts (vs. Initial Forecast)

- Revenue forecast is revised upward by JPY 120.0 billion.
- Adjusted operating profit at constant currency is revised upward by JPY 10.0 billion.
- Forecasts are revised upward for adjusted operating profit on a reported basis (JPY 42.0 billion), operating profit (JPY 39.0 billion) and profit attributable to owners of the parent company (JPY 32.0 billion).
- As announced in the initial forecast, the Company plans to offer an annual dividend per share of JPY 130.

Please refer to P. 17 'Data Sheets' for more financial figures.

## Masamichi Terabatake, President and Chief Executive Officer of the JT Group, said:

"JT Group delivered a robust performance in the first half, driven by strong business momentum. This was a result of continued market share gains in combustibles in many markets and continued tailwinds of strong industry volume trends due to travel restrictions in some mature markets.
"Considering this robust performance, we have revised our full year guidance upward.
"We have launched Ploom X, our next generation device for heated tobacco sticks in Japan, the world's largest heated tobacco market. Listening carefully to our consumers around the world, we have developed our first global model, offering a richer and enhanced taste, improved design, and a more intuitive user experience. Ploom X will gradually be rolled out across other markets.
"We are also making steady progress on several initiatives announced in February this year, including the rollout of our new operating model for the combined one tobacco business as well as measures to strengthen competitiveness in the Japan market. These initiatives will act as a catalyst for future growth while we continue to offer products and services which exceed our consumers' expectations."

[^0]
## 2021 Q2 Financial Results

## Consolidated Results

| (billions of JPY) | 2020 Q2 | 2021 Q2 | Variance | 2020 YTD | 2021 YTD | Variance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Revenue | 510.6 | 597.2 | +17.0\% | 1,030.2 | 1,144.5 | +11.1\% |
| Adjusted operating profit | 140.8 | 180.1 | +28.0\% | 287.6 | 358.2 | +24.5\% |
| Operating profit | 123.0 | 162.0 | +31.6\% | 252.0 | 322.1 | +27.8\% |
| Profit attributable to owners of the parent | 86.1 | 111.4 | +29.4\% | 172.5 | 225.2 | +30.5\% |
| Adjusted operating profit at constant FX | 140.8 | 178.2 | +26.6\% | 287.6 | 365.1 | +26.9\% |

## 2021 Q2

- Revenue

Revenue increased by $17.0 \%$ to JPY 597.2 billion driven by increases in the international tobacco, Japanese-domestic tobacco, pharmaceutical and processed food businesses.

- Adjusted operating profit

At constant currency, adjusted operating profit increased by $26.6 \%$ to JPY 178.2 billion driven by increases in the international tobacco, Japanese-domestic tobacco and processed food businesses, partially offset by a decrease in the pharmaceutical business.
On a reported basis, adjusted operating profit increased by $28.0 \%$ to JPY 180.1 billion driven by positive foreign currency impacts in the international tobacco business.

- Operating profit

Operating profit increased by $31.6 \%$ to JPY 162.0 billion driven by an increase in adjusted operating profit.

- Profit attributable to owners of the parent

Profit attributable to owners of the parent increased by $29.4 \%$ to JPY 111.4 billion driven by factors that include increases in operating profit and improved financing costs.

## 2021 YTD

- Revenue

Revenue increased by $11.1 \%$ to JPY 1,144.5 billion driven by increases in the international tobacco and Japanese-domestic tobacco businesses, partially offset by decreases in the pharmaceutical and processed food businesses.

- Adjusted operating profit

At constant currency, adjusted operating profit increased by $26.9 \%$ to JPY 365.1 billion driven by increases in the international tobacco, Japanese-domestic tobacco and processed food businesses, partially offset by a decrease in the pharmaceutical business.
On a reported basis, adjusted operating profit increased by $24.5 \%$ to JPY 358.2 billion, despite negative foreign currency impacts in the international tobacco business.

- Operating profit

Operating profit increased by $27.8 \%$ to JPY 322.1 billion driven by an increase in adjusted operating
profit.

- Profit attributable to owners of the parent

Profit attributable to owners of the parent increased by $30.5 \%$ to JPY 225.2 billion driven by factors that include increases in operating profit and improved financing cost.

In accordance with the requirements stipulated in IAS 29, the JT Group has been applying hyperinflationary accounting adjustments since Q3 2020, so the results for fiscal year 2021 on a reported basis include the impact of the adjustments. Starting from Q1 2021, results on a constant currency basis have been calculated to exclude amounts of revenue and profit that have increased due to hyperinflation in certain markets.

Results by Business Segment
International Tobacco Business

| (billions of Units, billions of JPY) | 2020 Q2 | 2021 Q2 | Variance | 2020 YTD | 2021 YTD | Variance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total shipment volume | 107.8 | 118.7 | +10.1\% | 211.9 | 228.9 | +8.0\% |
| GFB shipment volume | 68.8 | 79.8 | +16.1\% | 136.3 | 153.5 | +12.6\% |
| Core revenue ${ }^{1}$ | 314.0 | 387.3 | +23.3\% | 626.1 | 736.3 | +17.6\% |
| Adjusted operating profit ${ }^{1}$ | 110.3 | 136.6 | +23.8\% | 214.3 | 270.2 | +26.1\% |

Reference (millions of USD)

| Core revenue ${ }^{1}$ | 2,918 | $\mathbf{3 , 5 3 5}$ | $+21.1 \%$ <br> $(+15.0 \%)^{*}$ | 5,784 | $\mathbf{6 , 8 1 8}$ |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Adjusted operating profit ${ }^{1}$ | 1,025 | $\mathbf{1 , 2 4 7}$ | $+17.9 \%$ <br> $(+214.5 \%)^{*}$ <br> $(+22.1 \%)^{*}$ |  |  |

*at constant currency

## 2021 Q2

- Volume and market share ${ }^{2}$

Total shipment volume increased $10.1 \%$ including favorable inventory movements. Excluding inventory adjustments, total shipment volume increased $9.1 \%$ building on favorable industry volume trend comparisons in several markets and quarterly market share gains. Share grew across all key markets of France, Italy, Russia, Spain, Taiwan, Turkey and the UK, in addition to many others, notably Brazil, Canada, the Czech Republic, Germany, Hungary, the Philippines, Poland, Romania and Ukraine. GFB shipment volume increased $16.1 \%$, driven by strong growth from Winston (+14.5\%), Camel (+39.3\%) and Mevius (+9.9\%).

- Core revenue and adjusted operating profit ${ }^{1}$

Core revenue and adjusted operating profit increased $23.3 \%$ and $23.8 \%$, respectively, driven by solid volume, robust price/mix contribution as well as favorable currency movements.

On a USD basis, core revenue at constant currency increased $15.0 \%$, driven by a favorable volume contribution of USD 246 million and a positive price/mix variance of USD 192 million, notably from Canada, Iran, Kazakhstan, the Philippines, Romania, Turkey, the UK and Ukraine. At constant currency, adjusted operating profit grew by $22.1 \%$, driven by a positive volume contribution of USD 163 million and a favorable price/mix variance of USD 165 million, partially offset by continued investments in the heated tobacco sticks segment. On a reported basis, core revenue and adjusted operating profit increased $21.1 \%$ and $21.7 \%$, respectively.

## 2021 YTD

## - Volume and market share ${ }^{2}$

Total shipment volume increased $8.0 \%$ including favorable inventory movements. Excluding inventory adjustments, total shipment volume increased $7.1 \%$, driven by favorable industry volume trend comparisons in several markets, mainly due to on-going travel restrictions, and robust market share gains. Market share gains continued across many geographies, notably in in Austria, Brazil, Canada, the Czech Republic, France, Germany, Hungary, Italy, the Philippines, Poland, Romania, Serbia, Spain, Taiwan, Turkey, the UK and Ukraine. These positive factors more than offset the lower DutyFree shipment volumes resulting from COVID-19 measures. GFB shipment volume grew $12.6 \%$, fueled by the robust performance of Winston (+12.0\%), Camel (+24.6\%), LD (+3.4\%) and Mevius

- Core revenue and Adjusted operating profit ${ }^{1}$

Core revenue and adjusted operating profit increased $17.6 \%$ and $26.1 \%$, respectively, driven by a strong price/mix variance and a positive volume contribution, offsetting by unfavorable currency movements.

On a USD basis, core revenue at constant currency increased $14.5 \%$, driven by a robust volume contribution of USD 460 million and a positive price/mix variance of USD 379 million, notably from Canada, Iran, Kazakhstan, the Philippines, Russia, Turkey and Ukraine. At constant currency, adjusted operating profit grew $29.2 \%$, driven by a favorable price/mix variance of USD 346 million and a positive volume contribution of USD 311 million. On a reported basis, core revenue and adjusted operating profit increased $17.9 \%$ and $26.5 \%$, respectively.

International Tobacco Business
(Quarterly) Performance Review by Cluster

## South and West Europe

| (billions of Units, millions of USD) | 2020 Q2 | 2021 Q2 | Variance |
| :--- | :---: | :---: | :---: |
| Total shipment volume | 16.3 | $\mathbf{1 8 . 7}$ | $+14.5 \%$ |
| GFB shipment volume | 13.7 | $\mathbf{1 5 . 9}$ | $+16.5 \%$ |
| Core revenue | 493 | $\mathbf{6 2 1}$ | $+26.0 \%$ <br> $(+15.7 \%)^{*}$ |

## *at constant currency

- Volume and market share ${ }^{2}$

Total and GFB shipment volumes, including favorable inventory movements, increased $14.5 \%$ and $16.5 \%$, respectively. Excluding inventory adjustments, total shipment volume grew $7.0 \%$, driven by favorable industry volume trend comparisons versus the same quarter last year, and continued market share gains. Quarterly market share increased in Belgium, France, Greece, Italy, Luxembourg, the Netherlands, Spain and Switzerland.

## - Core revenue

Core revenue grew $26.0 \%$, driven by a positive volume contribution of USD 71 million, notably from Italy and Spain, and a favorable price/mix variance of USD 6 million. Excluding favorable currency movements of USD 50 million, core revenue increased $15.7 \%$.

## - By market ${ }^{2}$

In France, excluding inventory movements, total shipment volume decreased 4.7\% despite continued quarterly market share gains ( +1.8 ppt ) in cigarettes and fine cut. Factoring in favorable inventory adjustments, total, GFB and fine cut shipment volumes declined $4.3 \%, 4.7 \%$ and $16.3 \%$, respectively, due to the unfavorable industry volume trend comparison versus the same quarter last year. Currencyneutral core revenue declined, as a positive price/mix was offset by a negative volume contribution. Year-to-date total shipment volumes were up $5.3 \%$, or $4.0 \%$ excluding inventory movements, with GFB shipment volume increasing $6.1 \%$ and fine cut shipment volume declining 2.2\%. Year-on-year market share increased 3.2 ppt to $28.4 \%$, fueled by GFBs.

In Italy, excluding inventory movements, total shipment volume increased 7.7\% fueled by a favorable industry volume trend comparison versus the same period last year and solid quarterly market share gains (+1.2ppt) in both cigarettes and fine cut. Accounting for favorable inventory adjustments, total
and GFB shipment volumes increased $16.4 \%$ and $21.0 \%$, respectively, while fine cut shipment volume decreased $5.4 \%$. Currency-neutral core revenue increased, driven by a solid volume contribution and a favorable price/mix variance. Year-to-date total shipment volume grew $4.1 \%$, or $4.4 \%$ excluding inventory adjustments, with GFB shipment volume up $6.4 \%$ and fine cut down $0.5 \%$. Year-on-year market share increased 1.3ppt to $26.2 \%$, led by Winston.

In Spain, excluding inventory movements, total shipment volume grew 13.1\%, driven by a favorable industry volume trend comparison and strong quarterly market share gains (+1.5ppt). Factoring in favorable inventory adjustments, total, GFB and fine cut shipment volumes increased 41.4\%, 42.7\% and $5.5 \%$, respectively. Currency-neutral core revenue increased, driven by a strong volume contribution combined with a favorable price/mix variance. Year-to-date total shipment volume increased $12.2 \%$, or $4.8 \%$ excluding inventory movements. GFB and fine cut shipment volume increased $15.6 \%$ and $3.9 \%$ respectively. Year-on-year market share increased 1.4 ppt to $27.4 \%$, led by Winston and Camel.

## North and Central Europe

| (billions of Units, millions of USD) | 2020 Q2 | 2021 Q2 | Variance |
| :--- | :---: | :---: | :---: |
| Total shipment volume | 15.7 | $\mathbf{1 7 . 6}$ | $+12.4 \%$ |
| GFB shipment volume | 8.1 | $\mathbf{9 . 8}$ | $+20.2 \%$ |
| Core revenue | 609 | $\mathbf{7 7 8}$ | $+27.8 \%$ <br> $(+14.7 \%)^{*}$ |

*at constant currency

- Volume and market share ${ }^{2}$

Total and GFB shipment volumes increased $12.4 \%$ and $20.2 \%$, respectively, driven by favorable industry volume trend comparisons in several markets due to travel restrictions, notably in the UK, and continued market share gains. Quarterly market share grew in the Czech Republic, Germany, Hungary, Ireland, Poland and the UK.

- Core revenue

Core revenue grew $27.8 \%$ driven by a favorable volume contribution of USD 63 million, notably from Poland and the UK, combined with a positive price/mix variance of USD 26 million and favorable currency movements of USD 80 million. Excluding currency impacts, core revenue increased $14.7 \%$.

- By market ${ }^{2}$

In Germany, total and GFB shipment volumes both increased $0.9 \%$, driven by quarterly market share gains (+0.7ppt) in cigarettes and fine cut. Fine cut shipment volume declined $1.2 \%$ due to lower industry volume. Currency-neutral core revenue grew, driven by positive volume and price/mix contributions. Year-to-date shipment volumes grew $6.9 \%, 7.3 \%$ and $4.2 \%$ in total, GFB and fine cut respectively. Year-on-year market share grew 0.6ppt to $9.2 \%$ driven by Winston.

In the UK, total shipment volume increased $7.3 \%$, building on a favorable industry volume trend comparison, driven by travel restrictions, and quarterly market share gains (+0.9ppt). Cigarette and fine cut shipment volumes grew $7.9 \%$ and $5.3 \%$, respectively, led by B\&H Blue and Sterling. Currencyneutral core revenue increased, fueled by favorable volume and price/mix contributions. Year-to-date shipment volumes grew $8.3 \%$ and $12.8 \%$ in total and fine cut respectively. Year-on-year market share was up 1.1 ppt to $45.4 \%$.

CIS+

| (billions of Units, millions of USD) | 2020 Q2 | $\mathbf{2 0 2 1}$ Q2 | Variance |
| :--- | :---: | :---: | :---: |
| Total shipment volume | 32.1 | $\mathbf{3 3 . 0}$ | $+3.1 \%$ |
| GFB shipment volume | 21.7 | $\mathbf{2 3 . 3}$ | $+7.4 \%$ |
| Core revenue | 714 | $\mathbf{7 9 4}$ | $+11.2 \%$ <br> $(+12.1 \%)^{*}$ |

- Volume and market share ${ }^{2}$

Total shipment volume, excluding inventory movements, increased $5.6 \%$, driven by quarterly market share gains and favorable industry volume trend comparisons versus the same quarter last year. Factoring in unfavorable inventory adjustments, total and GFB shipment volumes increased $3.1 \%$ and $7.4 \%$, respectively. Quarterly market share grew in Azerbaijan, Romania, Russia, Serbia and Ukraine.

- Core revenue

Core revenue increased $11.2 \%$ driven by a favorable price/mix variance of USD 52 million, mainly from Kazakhstan, Romania and Ukraine, and a positive volume contribution of USD 35 million. Excluding unfavorable currencies of USD 7 million, core revenue grew $12.1 \%$.

- By market ${ }^{2}$

In Romania, total and GFB shipment volumes increased $18.2 \%$ and $14.7 \%$, respectively, driven by quarterly market share gains ( +1.1 ppt ). Positive volume and price/mix variances drove an increase in currency-neutral core revenue. Year-to-date shipment volumes grew $10.3 \%$ and $7.9 \%$ in total and GFB, respectively. Year-on-year market share reached $29.5 \%$, an increase of 1.2 ppt driven by Winston and Sobranie.

In Russia ${ }^{3}$, excluding inventory movements, total shipment volume increased $3.3 \%$, driven by quarterly total tobacco market share gains (+0.6ppt), mainly in combustibles, and lower illicit trade. The latter resulted in an improved total tobacco industry volume ${ }^{4}$ trend comparison, increasing an estimated $2.6 \%$. Accounting for unfavorable inventory adjustments, total shipment volume declined $0.5 \%$ while GFB shipment volume increased a robust $8.2 \%$, driven by the performance of Camel and LD. The distribution expansion of heated tobacco sticks in key accounts continued, strengthening the foundations ahead of the introduction of Ploom X later this year. Currency-neutral core revenue grew, driven by positive volume and price/mix contributions. Year-to-date total shipment volume increased $6.9 \%$, or $3.6 \%$ excluding inventory movements, and GFB shipment volume was up $17.6 \%$. Despite an improving trend over the last three quarters, year-on-year total tobacco market share declined to $36.4 \%$.

## Rest-of-the-World

| (billions of Units, millions of USD) | 2020 Q2 | 2021 Q2 | Variance |
| :--- | :---: | :---: | :---: |
| Total shipment volume | 43.8 | $\mathbf{4 9 . 4}$ | $+12.9 \%$ |
| GFB shipment volume |  | 25.3 | $\mathbf{3 0 . 9}$ |
| Core revenue ${ }^{1}$ | 1,102 | $\mathbf{1 , 3 4 2}$ | $+21.9 \%$ <br> $(+16.7 \%)^{*}$ |

*at constant currency

## - Volume and market share ${ }^{2}$

Total shipment volume increased $11.2 \%$ when excluding inventory movements, driven by favorable industry volume trend comparisons in several markets and solid quarterly market share gains. Factoring in favorable inventory adjustments, total and GFB shipment volumes increased $12.9 \%$ and $21.9 \%$, respectively, driven by Winston, Camel, Mevius and LD. Quarterly market share increased across many markets, notably in Brazil, Cambodia, Canada, Indonesia, Lebanon, the Philippines, Saudi Arabia, Singapore, South Korea, Taiwan, Tanzania and Turkey.

- Core revenue ${ }^{1}$

Core revenue increased $21.8 \%$, driven by a favorable price/mix variance of USD 108 million, notably in Canada, the Philippines and Turkey, combined with a positive volume contribution of USD 76 million and favorable currencies of USD 56 million. Excluding currency impacts, core revenue increased $16.7 \%$.

- By market ${ }^{2}$

In Iran, excluding inventory movements, total shipment volume grew $15.6 \%$, driven by stronger industry volume trends. Accounting for favorable inventory adjustments, total and GFB shipment volumes increased $16.1 \%$ and $24.1 \%$, respectively. Currency-neutral core revenue increased, fueled by volume and price/mix contributions. Year-to-date total shipment volume grew $9.3 \%$, or $9.6 \%$ excluding inventory adjustments, and GFB shipment volume was up 15.0\%. Year-on-year market share declined 0.9 ppt to $59.0 \%$.

In Taiwan, total shipment volume increased $1.0 \%$, or declined $1.3 \%$ when excluding inventory movements. GFB shipment volume grew $0.5 \%$ and quarterly market share gains continued (+0.6ppt), in a resilient industry in terms of volume. Currency-neutral core revenue increased, driven by favorable volume and price/mix variances. Year-to-date total shipment volume grew $6.6 \%$, or $5.2 \%$ excluding inventory adjustments, and GFB shipment volume was up $5.3 \%$. Year-on-year market share increased by 1.7 ppt to $48.2 \%$, driven by Mevius, LD and Winston.

In Turkey, excluding inventory movements, total shipment volume grew $16.8 \%$ supported by an improved industry volume comparison and quarterly market share gains (+1.5ppt), driven by Winston. Accounting for favorable inventory adjustments, total and GFB shipment volumes increased 26.2\% and $26.5 \%$, respectively. Currency-neutral core revenue grew driven by favorable volume and price/mix contributions. Year-to-date total shipment volume increased 13.1\%, or $13.9 \%$ excluding inventory adjustments, and GFB shipment volume grew 13.7\%. Year-on-year market share increased 0.3ppt to 27.0\%.

[^1]Canada, the Czech Republic, Germany, Greece, Hungary, Iran, Ireland, Netherlands, Philippines, Romania, Russia, Tanzania, Turkey and the UK are on a 12-month rolling average and 2-month average at the end of May 2021. 12month and 3-month shares of market growth for 2021 are calculated against 12-month and 3-month shares of market at the end of the respective period in 2020.
${ }^{3}$ From Q1 2021 onwards, shipment volume and market share data for Russia reflect total tobacco figures, i.e. cigarettes and heated tobacco sticks. 2020 data has been adjusted accordingly.
${ }^{4}$ Source: JTI estimates based on Apr.-May 2021 total tobacco data versus the same period last year.

| (billions of units, billions of JPY) | 2020 Q2 | 2021 Q2 | Variance | 2020 YTD | 2021 YTD | Variance |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| Cigarette industry volume $^{5}$ | 28.2 | $\mathbf{2 6 . 9}$ | $-4.8 \%$ | 57.0 | $\mathbf{5 1 . 9}$ | $-8.9 \%$ |
| Cigarette sales volume | 17.0 | $\mathbf{1 6 . 0}$ | $-5.7 \%$ | 34.2 | $\mathbf{3 0 . 9}$ | $-9.5 \%$ |
| Core revenue | 123.0 | $\mathbf{1 3 2 . 2}$ | $+\mathbf{+ 7 . 5 \%}$ | 248.8 | $\mathbf{2 5 6 . 4}$ | $+3.0 \%$ |
| Adjusted operating profit | 38.6 | $\mathbf{5 3 . 3}$ | $\mathbf{+ 3 8 . 0 \%}$ | 81.8 | $\mathbf{1 0 1 . 3}$ | $+23.8 \%$ |

## 2021 Q2

- Cigarette sales volume

Cigarette industry volume ${ }^{5}$ decreased by $4.8 \%$, mainly due to a natural decline trend, growth in the RRP category and the impact of price revisions in October 2020.
Cigarette sales volume decreased by $5.7 \%$ due to cigarette industry volume contraction and a loss in market share.
Cigarette market share ${ }^{5}$ decreased by 0.6 ppt year on year to $59.5 \%$ due to growth in the RRP category and intense competition in the value segment followed by downtrading.

- Reduced-Risk Products (RRP) performance

RRP industry volume ${ }^{6}$ in Japan was 11.2 billion units, an increase of 1.3 billion units year on year. The overall RRP market size is estimated to represent $29.3 \%$ (shipment basis) of total tobacco industry volume. JT's RRP sales volume was 1.1 billion units, an increase of 0.2 billion units year on year. JT's market share ${ }^{5}$ in the RRP category is estimated to be $9.9 \%$ (shipment basis).
In July, Ploom X, the next generation heated tobacco device, was launched.

- Core revenue and adjusted operating profit

Core revenue increased by $7.5 \%$, mainly driven by a positive cigarette price/mix variance of JPY 13.3 billion and an increase in RRP-related revenue, despite an unfavorable cigarette sales volume variance of JPY 6.2 billion. RRP-related revenue increased by JPY 1.6 billion year on year to JPY 14.6 billion, driven by an increase in RRP sales volume.

Adjusted operating profit increased by $38.0 \%$, mainly driven by a positive cigarette price/mix variance of JPY 13.3 billion; an increase in RRP-related revenue; and investments originally skewed in the second half to support the expansion of Ploom X, resulting in reduced sales promotion expenses. This was partially offset by an unfavorable cigarette sales volume variance of JPY 5.1 billion.

## 2021 YTD

- Cigarette sales volume

Cigarette industry volume ${ }^{5}$ decreased by $8.9 \%$, mainly due to a natural decline trend, growth in the RRP category and the impact of price revisions in October 2020.
Cigarette sales volume decreased by $9.5 \%$ due to cigarette industry volume contraction, growth in the RRP category and a loss in market share.
Cigarette market share ${ }^{5}$ decreased by 0.4 ppt, down to $59.5 \%$ due to growth in the RRP category and intense competition in the value segment followed by downtrading.

- Reduced-Risk Products (RRP) performance

RRP industry volume ${ }^{6}$ in Japan was 21.7 billion units, an increase of 2.6 billion units year on year. The overall RRP market size is estimated to represent $29.5 \%$ (shipment basis) of total tobacco industry volume. JT's RRP sales volume was 2.1 billion units, an increase of 0.3 billion units year on year. JT's market share ${ }^{5}$ in the RRP category is estimated to be $9.8 \%$ (shipment basis).

## - Core revenue and adjusted operating profit

Core revenue increased by $3.0 \%$, driven by a positive cigarette price/mix variance of JPY 25.6 billion and an increase in RRP-related revenue, despite an unfavorable cigarettes sales volume variance of JPY 20.6 billion and lower sales in the domestic Duty-Free and China businesses. RRP-related revenue increased by JPY 3.4 billion year on year to JPY 29.3 billion, driven by an increase in RRP sales volume.
Adjusted operating profit increased by $23.8 \%$, mainly driven by a positive cigarette price/mix variance of JPY 25.6 billion, an increase in RRP-related revenue and investments originally skewed in the second half to support the expansion of Ploom X, resulting in reduced sales promotion expenses. This was partially offset by an unfavorable cigarette sales volume variance of JPY 17.2 billion.

[^2]| (billions of JPY) | 2020 Q2 | 2021 Q2 | Variance | 2020 YTD | 2021 YTD | Variance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Revenue | 16.5 | 17.4 | +5.1\% | 37.3 | 37.1 | -0.6\% |
| Adjusted operating profit | 1.4 | -0.7 | - | 7.9 | 3.6 | -55.2\% |

## 2021 Q2

- Revenue and adjusted operating profit

Revenue increased 5.1\% mainly driven by top-line growth in our consolidated subsidiary, Torii Pharmaceutical, which more than offset a decrease in overseas royalty income.
Adjusted operating profit decreased by JPY 2.0 billion, due to recognition of losses associated with the termination of the development of a licensed compound as well as a Torii Pharmaceutical's decrease in profit.

## 2021 YTD

- Revenue and adjusted operating profit

Revenue was almost flat as the top-line growth in Tori Pharmaceutical was partially offset by the decrease in overseas royalty income.
Adjusted operating profit decreased 55.2\% for the reasons mentioned for Q2.

Processed Food Business

| (billions of JPY) | 2020 Q2 | 2021 Q2 | Variance | 2020 YTD | 2021 YTD | Variance |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| Revenue | 35.1 | 36.7 | $+4.5 \%$ | 71.8 | $\mathbf{7 0 . 4}$ | $-1.9 \%$ |
| Adjusted operating profit | -0.1 | $\mathbf{1 . 1}$ | - | 0.0 | $\mathbf{1 . 5}$ | $+316.9 \%$ |

## 2021 Q2

- Revenue and adjusted operating profit

Revenue increased $4.5 \%$ mainly led by a slight sales recovery in food-service products within the frozen and ambient food as well as the seasonings businesses, in addition to the bakery business compared to the previous year. The sales, however, did not recover to the levels before COVID-19.
Adjusted operating profit increased by JPY 1.2 billion mainly led by the top-line growth of these businesses and a decrease in SG\&A expenses, including a favorable comparison of impairment losses in the bakery business in the previous year.

## 2021 YTD

- Revenue and adjusted operating profit

Revenue decreased $1.9 \%$ mainly due to a relative decline in demand for household products in the frozen and ambient food business, which had temporarily increased in the same period of the previous year.
Adjusted operating profit increased by JPY 1.1 billion mainly led by a decrease in SG\&A expenses, including a favorable comparison of impairment losses in the bakery business in the previous year, which more than offset the top-line decline.

## FY2021 Revised Forecasts

## Consolidated

| (billions of JPY) | 2021 Forecast |  | Variance vs. Initial Forecast | Variance vs. 2020 Results |
| :---: | :---: | :---: | :---: | :---: |
| Revenue | 2,080.0 | 2,200.0 | +120.0 | +5.1\% |
| Adjusted operating profit | 475.0 | 517.0 | +42.0 | +6.2\% |
| Operating profit | 363.0 | 402.0 | +39.0 | -14.3\% |
| Profit attributable to owners of the parent | 240.0 | 272.0 | +32.0 | -12.3\% |
| Free cash flow | 315.0 | 383.0 | +68.0 |  |
| Adjusted operating profit at constant FX | 512.0 | 522.0 | +10.0 | +7.2\% |

- Revenue

Revenue forecast is revised upward by JPY 120.0 billion to JPY 2,200.0 billion driven by the upward revisions in the international tobacco and pharmaceutical businesses, partially offset by the downward revisions in the Japanese-domestic tobacco and processed food businesses. As a result, revenue is now expected to increase by $5.1 \%$ year on year.

- Adjusted operating profit

Adjusted operating profit at constant currency is revised upward by JPY 10.0 billion to JPY 522.0 billion, resulting in a $7.2 \%$ increase year on year, driven by the upward revisions in the international tobacco business, partially offset by the expected partial reclassification of investments related to the consolidation of IT infrastructure between JT and JTI from capital expenditures to expenses.
On a reported basis, adjusted operating profit is revised upward by JPY 42.0 billion to JPY 517.0 billion, resulting in a $6.2 \%$ increase year-on-year, driven by the upward revisions in adjusted operating profit at constant currency and revised currency assumptions.

- Operating profit and Profit attributable to owners of the parent

Operating profit is revised upward by JPY 39.0 billion to JPY 402.0 billion, driven by the upward revision in adjusted operating profit, resulting in a $14.3 \%$ decline year-on-year.
Profit attributable to owners of the parent company is revised upward by JPY 32.0 billion to JPY 272.0 billion driven by the upward revisions in the operating profit and improved financing costs. This represents a $12.3 \%$ decline year on year.

## - Free cash flow

Free cash flow is revised upward by JPY 68.0 billion to JPY 383.0 billion, driven by the upward revision in adjusted operating profit and a revision in capital expenditures.

In accordance with the requirements stipulated in IAS 29, hyperinflationary accounting adjustments have been applied to the forecasts on a reported basis since Q3 2020. The forecasts on a constant currency basis have been calculated to exclude amounts of revenue and profit that have been increased due to hyperinflation in certain markets.

## Forecasts by Business Segment

## International Tobacco Business

| (billions of JPY) | 2021 Forecast <br> Initial Revised |  | Variance vs. Initial Forecast | Variance vs. 2020 Results |
| :---: | :---: | :---: | :---: | :---: |
| Total shipment volume | Decline mid 3\% | Almost flat |  |  |
| GFB shipment volume | Approx. -1\% | Approx. +3\% |  |  |
| Core revenue ${ }^{7}$ | 1,230.0 | 1,360.0 | +130.0 | +8.7\% |
| Adjusted operating profit ${ }^{7}$ | 332.0 | 377.0 | +45.0 | +10.6\% |

Reference (millions of USD)

| Core revenue | 11,900 | $\mathbf{1 2 , 5 0 0}$ | +600 | $+6.6 \%$ <br> $(+3.2 \%)^{*}$ |
| :--- | :---: | :---: | :---: | :---: |
| Adjusted operating profit ${ }^{7}$ | 3,220 | $\mathbf{3 , 4 8 0}$ | +260 | $+9.4 \%$ <br> $(+11.6 \%)^{*}$ |

*at constant currency

- Volume

The forecasts for total and GFB shipment volumes are revised upwards to account for the stronger first half performance, driven by favorable industry volume trend comparisons in several markets, notably from the slower easing of COVID-19 restrictions, and continued market share gains across many markets. Factoring in a deterioration in industry volume trends in the second half, mainly due to a more challenging comparative related to different levels of COVID-19 restrictions in several markets, total shipment volume is now expected to be almost flat year-on-year and GFB shipment volume is forecast to increase approximately $3 \%$.

- Core revenue and adjusted operating profit ${ }^{7}$

On a JPY basis, the forecasts for core revenue and adjusted operating profit are revised upward by JPY 130.0 billion and JPY 45.0 billion respectively, mainly driven by a stronger first half performance and revised FX assumptions. As a result, core revenue and adjusted operating profit will increase $8.7 \%$ and $10.6 \%$, respectively, versus the previous year.

On a USD basis, core revenue and adjusted operating profit are revised upwards by USD 600 million and USD 260 million, respectively, driven by a stronger first half volume performance and revised FX assumptions, notably GBP, IRR and RUB. Investments in the second half of the year are expected to exceed those in the first half and will result in a year-on-year increase to support the expansion of heated tobacco sticks. On a currency-neutral basis, core revenue and adjusted operating profit are now expected to increase by $3.2 \%$ and $11.6 \%$, respectively.

[^3]| (billions of JPY) | 2021 Forecast <br> Initial |  | Variance vs. Initial Forecast | Variance vs. 2020 Results |
| :---: | :---: | :---: | :---: | :---: |
| Cigarette industry volume ${ }^{8}$ | Decline over 8.0\% | Decline over 9.0\% |  |  |
| Cigarette sales volume | Decline upper 7.0\% | Decline slightly less than 11.0\% |  |  |
| Core revenue | 520.0 | 510.0 | -10.0 | -1.1\% |
| Adjusted operating profit | 176.0 | 176.0 | - | +4.7\% |

- Volume

The cigarette industry volume ${ }^{8}$ decline assumption is revised from over $8.0 \%$ to over $9.0 \%$ reflecting growth in the RRP category beyond the initial expectations. JT's estimate for overall RRP market size is revised from upper $20 \%$ range to approx. $30 \%$ of the full year total tobacco industry volume.
The total tobacco industry volume ${ }^{8}$ decline assumption is revised from over $4.0 \%$ to upper $3.0 \%$ reflecting a resilient industry volume in the first half of this year.
The assumption on JT cigarette sales volume decline is revised from upper $7.0 \%$ to slightly less than $11.0 \%$, mainly due to growth in the RRP category beyond the initial expectations and intense competition in the value segment followed by downtrading. The JT RRP sales volume estimate remains unchanged at over 4.5 billion units.

- Core revenue and adjusted operating profit

The core revenue forecast is revised downward by JPY 10.0 billion now representing a decrease of $1.1 \%$ versus the previous year. This is due to intense competition in the value segment followed by downtrading, a decrease in JT cigarette sales volume due to growth in the RRP category and the protracted negative impact of COVID-19 on the top line in the Duty-Free business.
Adjusted operating profit forecast remains unchanged at a year-on-year increase at $4.7 \%$ despite accounting for necessary investments in the second half of this year, notably for sales and promotion activities of Ploom X, which are expected to be offset by efficient cost execution and optimised investments in priority activities.

[^4]| (billions of JPY) | 2021 Forecast <br> Initial Revised |  | Variance vs. Initial Forecast | Variance vs. 2020 Results |
| :---: | :---: | :---: | :---: | :---: |
| Revenue | 76.5 | 77.0 | +0.5 | -2.5\% |
| Adjusted operating profit | 7.0 | 7.0 | - | -59.2\% |

- Revenue and adjusted operating profit

The revenue forecast is revised upward by JPY 0.5 billion as overseas royalty income is expected to be better than the initial forecast. The revised forecast represents a decrease of $2.5 \%$ versus the previous year.
Adjusted operating profit forecast remains unchanged despite the top-line growth due to recognition of losses associated with the termination of the development of a licensed compound. The forecast represents a decrease of $59.2 \%$ versus the previous year.

Processed Food Business

| (billions of JPY) | 2021 Forecast Initial Revised |  | Variance vs. Initial Forecast | Variance vs. 2020 Results |
| :---: | :---: | :---: | :---: | :---: |
| Revenue | 151.0 | 150.0 | -1.0 | +0.4\% |
| Adjusted operating profit | 3.0 | 3.0 | - | - |

- Revenue and adjusted operating profit

Revenue is revised downward by JPY 1.0 billion, representing an increase of $0.4 \%$ versus the previous year, considering the continued impact by factors including the declaration of a state of emergency. The revision also reflects the sales recovery outlook, which is expected to be slower than that initially anticipated, in food-service products in the frozen and ambient food; seasonings; and the bakery businesses despite the expected growth in sales of household products in the frozen and ambient food business.
Adjusted operating profit forecast remains unchanged despite the downward revision of revenue, and it will be achieved by committing to an improvement in product mix in the frozen and ambient food business as well as effective cost execution and investments.

## Data Sheets

## Results for 2021 Second Quarter

In accordance with the requirements stipulated in IAS 29, the JT Group has been applying hyperinflationary accounting adjustments since Q3 2020, so the results for fiscal year 2021 on a reported basis include the impact of the adjustments. Starting from Q1 2021, results on a constant currency basis have been calculated to exclude amounts of revenue and profit that have increased due to hyperinflation in certain markets.

1. Summary of Consolidated results

|  | 2020 <br> Q2 YTD | 2021 <br> Q2 YTD | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| Revenue | $1,030.2$ | $1,144.5$ | +114.3 | $+11.1 \%$ |
| Operating profit | 252.0 | 322.1 | +70.1 | $+27.8 \%$ |
| Adjusted operating profit | 287.6 | 358.2 | +70.6 | $+24.5 \%$ |
| Profit before income taxes | 226.0 | 314.1 | +88.1 | $+39.0 \%$ |
| Profit | 173.4 | 225.9 | +52.6 | $+30.3 \%$ |
| Profit (attributable to owners of the parent company) | 172.5 | 225.2 | +52.7 | $+30.5 \%$ |
| Basic EPS*(JPY) | 97.23 | 126.92 | +29.69 | $+30.5 \%$ |

*Based on profit attributable to owners of the parent company
[Reference] Consolidated results

|  | 2020 <br> Q2 YTD | 2021 <br> Q2 YTD | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| Adjusted operating profit at constant FX | 287.6 | 365.1 | +77.5 | $+26.9 \%$ |


| 2. Results by business segment | (Unit: JPY billion) |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} 2020 \\ \text { Q2 YTD } \end{gathered}$ | $\begin{gathered} 2021 \\ \text { Q2 YTD } \end{gathered}$ | Variance (abs) | Variance (\%) |
| Consolidated: revenue | 1,030.2 | 1,144.5 | +114.3 | +11.1\% |
| Japanese-domestic tobacco | 267.7 | 275.3 | +7.6 | +2.8\% |
| Core revenue | 248.8 | 256.4 | +7.5 | +3.0\% |
| International tobacco | 651.9 | 760.9 | +108.9 | +16.7\% |
| Core revenue | 626.1 | 736.3 | +110.2 | +17.6\% |
| Pharmaceutical | 37.3 | 37.1 | -0.2 | -0.6\% |
| Processed food | 71.8 | 70.4 | -1.4 | -1.9\% |
| Others | 1.4 | 0.9 | -0.5 | -37.8\% |
| Consolidated: operating profit | 252.0 | 322.1 | +70.1 | +27.8\% |
| Japanese-domestic tobacco | 73.7 | 93.1 | +19.4 | +26.4\% |
| International tobacco | 187.3 | 243.4 | +56.1 | +29.9\% |
| Pharmaceutical | 7.2 | 3.8 | -3.4 | -47.8\% |
| Processed food | 0.3 | 0.5 | +0.1 | +34.8\% |
| Others/Elimination | -16.5 | -18.6 | -2.1 | - |
| Adjustments, total | -35.6 | -36.1 | -0.5 |  |
| Japanese-domestic tobacco | -8.1 | -8.1 | -0.0 |  |
| International tobacco | -27.0 | -26.9 | +0.2 |  |
| Pharmaceutical | -0.7 | 0.2 | +0.9 |  |
| Processed food | -0.0 | -1.0 | -1.0 |  |
| Others/Elimination | 0.2 | -0.4 | -0.6 |  |
| Consolidated: adjusted operating profit | 287.6 | 358.2 | +70.6 | +24.5\% |
| Japanese-domestic tobacco | 81.8 | 101.3 | +19.5 | +23.8\% |
| International tobacco | 214.3 | 270.2 | +55.9 | +26.1\% |
| Pharmaceutical | 7.9 | 3.6 | -4.4 | -55.2\% |
| Processed food | 0.3 | 1.5 | +1.1 | +316.9\% |
| Others/Elimination | -16.8 | -18.3 | -1.5 | - |


| [Reference] International tobacco business | (Unit: USD million) |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} 2020 \\ \text { Q2 YTD } \end{gathered}$ | $\begin{gathered} 2021 \\ \text { Q2 YTD } \end{gathered}$ | Variance (abs) | Variance (\%) |
| Core revenue | 5,784 | 6,818 | +1,034 | +17.9\% |
| Core revenue at constant FX | 5,784 | 6,623 | +839 | +14.5\% |
| Adjusted operating profit | 1,980 | 2,505 | +524 | +26.5\% |
| Adjusted operating profit at constant FX | 1,980 | 2,560 | +579 | +29.2\% |

Results for 2021 Second Quarter
3. Depreciation and amortization*

|  | 2020 <br> Q2 YTD | 2021 <br> Q2 YTD | Variance (abs) |
| :--- | ---: | ---: | ---: |
| Consolidated: depreciation and amortization | 81.1 | 81.9 | +0.9 |
| Japanese-domestic tobacco billion) |  |  |  |
| International tobacco | 26.7 | 25.0 | -1.7 |
| Pharmaceutical | 47.4 | 50.6 | +3.3 |
| Processed food | 2.6 | 2.5 | -0.2 |
| Others/Elimination | 3.3 | 3.0 | -0.2 |

*Excluding depreciation from lease transactions
4. Consolidated financial position

|  | 2020 Dec. end | 2021 Jun. end | Variance (abs) |
| :--- | ---: | ---: | ---: |
| Total assets | $5,381.4$ | $5,538.9$ | +157.5 |
| Total equity | $2,599.5$ | $2,862.8$ | +263.3 |
| Equity attributable to owners of the parent company | $2,522.8$ | $2,786.1$ | +263.3 |
| BPS (attributable to owners of the parent company) (JPY) | $1,421.92$ | $1,570.05$ | +148.13 |

5. Liquidity and interest-bearing debt
(Unit: JPY billion)

|  | 2020 Dec. end | 2021 Jun. end | Variance (abs) |
| :--- | ---: | ---: | ---: |
| Liquidity | 548.3 | 493.3 | -55.0 |
| Interest-bearing debt | 958.9 | 927.0 | -31.9 |

6. Consolidated cash flow (Unit: JPY billion)

|  | (Unit: JPY bilion) <br> Q2 YTD |  | 2021 <br> Q2 YTD |
| :--- | ---: | ---: | ---: |
| Variance (abs) |  |  |  |
| Cash flows from investing activities | 126.6 | 174.9 | +48.2 |
| Cash flows from financing activities | -27.9 | -46.5 | -18.6 |
| Cash and cash equivalents, beginning of the year | -25.0 | -212.7 | -187.7 |
| Foreign currency translation adj. on cash \& cash equivalents | 357.2 | 538.8 | +181.7 |
| Cash and cash equivalents, end of the year | -23.2 | 26.1 | +49.3 |
| FCF | 407.7 | 480.7 | +73.0 |

7. Capital expenditures
(Unit: JPY billion)

|  | 2020 <br> Q2 YTD | 2021 <br> Q2 YTD | Variance (abs) |
| :--- | ---: | ---: | ---: |
| Consolidated: capital expenditures | 45.5 | 38.8 | -6.7 |
| Japanese-domestic tobacco | 8.7 | 7.5 | -1.2 |
| International tobacco | 22.9 | 23.7 | +0.8 |
| Pharmaceutical | 7.8 | 4.0 | -3.8 |
| Processed food | 4.0 | 3.9 | -0.1 |
| Others/Elimination | 2.1 | -0.3 | -2.4 |

8. FX actual (Reference information)

|  | 2020 <br> Q2 YTD | 2021 <br> Q2 YTD | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| USD/JPY | 108.23 | 107.82 | -0.41 | $-0.4 \%$ |
| USD/RUB | 69.24 | 74.28 | +5.04 | $-6.8 \%$ |
| USD/GBP | 0.79 | 0.72 | -0.07 | $+10.2 \%$ |
| USD/EUR | 0.91 | 0.83 | -0.08 | $+9.4 \%$ |
| USD/CHF | 0.97 | 0.91 | -0.06 | $+6.4 \%$ |
| USD/TWD | 30.01 | 28.03 | -1.98 | $+7.1 \%$ |
| USD/TRY | 6.48 | 7.87 | +1.39 | $-17.7 \%$ |
| USD/IRR | 139,706 |  | $*$ |  |

EUR/IRR is converted to USD/IRR in table by using cross rate
*The closing currency rates for the month ended June 2021 have been applied when converting financial statements for subsidiaries located in hyperinflationary economies to the US dollar. Similarly, the month-end rates are also applied upon conversions from the US dollar to the Japanese yen. (USD/IRR: 217,892, USD/JPY: 110.58)

## FY2021 Revised Forecasts (as of July 30, 2021)

In accordance with the requirements stipulated in IAS 29, hyperinflationary accounting adjustments have been applied to the forecasts on a reported basis since Q3 2020. The forecasts on a constant currency basis have been calculated to exclude amounts of revenue and profit that have been increased due to hyperinflation in certain markets.

## 1. Summary of consolidated forecasts

(Unit: JPY billion)

|  | 2020 Results | 2021 Revised <br> Forecasts | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| Revenue | $2,092.6$ | $2,200.0$ | +107.4 | $+5.1 \%$ |
| Operating profit | 469.1 | 402.0 | -67.1 | $-14.3 \%$ |
| Adjusted operating profit | 487.0 | 517.0 | +30.0 | $+6.2 \%$ |
| Profit (attributable to owners of the parent company) | 310.3 | 272.0 | -38.3 | $-12.3 \%$ |

[Reference] Consolidated forecast

| (Unit: JPY billion) |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: |
| Adjusted operating profit at constant FX | 2020 Results | 2021 Revised <br> Forecasts | Variance (abs) | Variance (\%) |

## 2. EPS, DPS, ROE

(Unit: JPY)

|  | 2020 Results | 2021 Revised <br> Forecasts | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| Basic EPS* | 174.88 | 153.29 | -21.59 | $-12.3 \%$ |
| DPS | 154 | 130 | -24.00 | $-15.6 \%$ |
| ROE* $^{2}$ | $12.0 \%$ | $10.6 \%$ | $-1.3 \% p p t$ |  |

*Based on profit attributable to owners of the parent company
3. Forecasts by business segment
(Unit: JPY billion)

|  | 2020 Results | 2021 Revised Forecasts | Variance (abs) | Variance (\%) |
| :---: | :---: | :---: | :---: | :---: |
| Consolidated: revenue | 2,092.6 | 2,200.0 | +107.4 | +5.1\% |
| Japanese-domestic tobacco | 555.6 | 550.0 | -5.6 | -1.0\% |
| Core revenue | 515.7 | 510.0 | -5.7 | -1.1\% |
| International tobacco | 1,306.2 | 1,420.0 | +113.8 | +8.7\% |
| Core revenue | 1,250.8 | 1,360.0 | +109.2 | +8.7\% |
| Pharmaceutical | 79.0 | 77.0 | -2.0 | -2.5\% |
| Processed food | 149.3 | 150.0 | +0.7 | +0.4\% |
| Others | 2.5 | 3.0 | +0.5 | +21.3\% |
| Consolidated: operating profit | 469.1 | 402.0 | -67.1 | -14.3\% |
| Japanese-domestic tobacco | 151.8 | 114.0 | -37.8 | -24.9\% |
| International tobacco | 296.4 | 321.0 | +24.6 | +8.3\% |
| Pharmaceutical | 16.5 | 7.0 | -9.5 | -57.5\% |
| Processed food | -0.8 | 2.0 | +2.8 | - |
| Others/Elimination | 5.1 | -42.0 | -47.1 | - |
| Consolidated: adjusted operating profit | 487.0 | 517.0 | +30.0 | +6.2\% |
| Japanese-domestic tobacco | 168.1 | 176.0 | +7.9 | +4.7\% |
| International tobacco | 340.9 | 377.0 | +36.1 | +10.6\% |
| Pharmaceutical | 17.2 | 7.0 | -10.2 | -59.2\% |
| Processed food | -0.8 | 3.0 | +3.8 | - |
| Others/Elimination | -38.4 | -46.0 | -7.6 | - |

[Reference] International tobacco business
(Unit: USD million)

|  | 2020 Results | 2021 Revised <br> Forecasts | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| Core revenue | 11,724 | 12,500 | +776 | $+6.6 \%$ |
| Core revenue at constant FX | 11,724 | 12,100 | +376 | $+3.2 \%$ |
| Adjusted operating profit | 3,181 | 3,480 | +299 | $+9.4 \%$ |
| Adjusted operating profit at constant FX | 3,181 | 3,550 | +369 | $+11.6 \%$ |

FY2021 Revised Forecasts
(as of July 30, 2021)
4. Free cash flow
(Unit: JPY billion)

|  | 2020 Results | 2021 Revised <br> Forecasts | Variance (abs) |
| :--- | ---: | ---: | ---: |
| FCF | 503.9 | 383.0 | -120.9 |

5. Capital expenditures
(Unit: JPY billion)

|  | 2020 Results | 2021 Revised <br> Forecasts | Variance (abs) |
| :--- | ---: | ---: | ---: |
| Consolidated: capital expenditures | 112.9 | 132.0 | +19.1 |
| Japanese-domestic tobacco | 21.1 | 28.0 | +6.9 |
| International tobacco | 66.6 | 82.0 | +15.4 |
| Pharmaceutical | 9.1 | 6.0 | -3.1 |
| Processed food | 8.0 | 14.0 | +6.0 |
| Others/Elimination | 8.2 | 2.0 | -6.2 |

## 6. Assumptions of 2020 Forecast

2021 Japanese-domestic tobacco business

- Industry volume: a decrease of an upper 3\% range (vs. 2020: 155.0 BnU)
- Cigarette industry volume: a decrease of a lower 9\% range (vs. 2020:114.9 BnU)
- JT cigarette sales volume : a decrease of a slightly less than 11\% (vs. 2020 : 68.7 BnU )
- Reduced-Risk Products market share in tobacco industry (shipment basis) : approx. 30\% (2020: approx. 26\%)
- JT RRP sales volume : over 4.5 BnU stick equivalent

2021 International tobacco business

- Total shipment volume : almost flat (vs. 2020: 435.7 BnU)
- GFB shipment volume : an increase of approx. 3\% (vs. 2020: 282.0 BnU)
<FX assumptions>

|  | 2020 Results | 2021 Revised <br> Forecasts | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| USD/JPY | 106.76 | 108.91 | +2.15 | $+2.0 \%$ |
| USD/RUB | 72.07 | 74.00 | +1.93 | $-2.6 \%$ |
| USD/GBP | 0.78 | 0.72 | -0.06 | $+8.3 \%$ |
| USD/EUR | 0.88 | 0.83 | -0.05 | $+5.7 \%$ |
| USD/CHF | 0.94 | 0.91 | -0.03 | $+3.2 \%$ |
| USD/TWD | 29.47 | 28.00 | -1.47 | $+5.2 \%$ |
| USD/TRY | 7.01 | 8.60 | +1.59 | $-18.5 \%$ |

## FY2021 Revised Forecasts

## vs Initial Forecasts

(as of July 30, 2021)
In accordance with the requirements stipulated in IAS 29, hyperinflationary accounting adjustments have been applied to the forecasts on a reported basis since Q3 2020. The forecasts on a constant currency basis have been calculated to exclude amounts of revenue and profit that have been increased due to hyperinflation in certain markets.

1. Summary of consolidated forecasts
(Unit: JPY billion)

|  | 2021 Initial <br> Forecasts | 2021 Revised <br> Forecasts | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| Revenue | $2,080.0$ | $2,200.0$ | +120.0 | $+5.8 \%$ |
| Operating profit | 363.0 | 402.0 | +39.0 | $+10.7 \%$ |
| Adjusted operating profit | 475.0 | 517.0 | +42.0 | $+8.8 \%$ |
| Profit (attributable to owners of the parent company) | 240.0 | 272.0 | +32.0 | $+13.3 \%$ |

[Reference] Consolidated forecast

|  | 2021 Initial <br> Forecasts | 2021 Revised <br> Forecasts | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| Adjusted operating profit at constant FX | 512.0 | 522.0 | +10.0 | $+2.0 \%$ |

## 2. EPS, DPS, ROE

(Unit: JPY)

|  | 2021 Initial <br> Forecasts | 2021 Revised <br> Forecasts | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| Basic EPS | 135.30 | 153.29 | +17.99 | $+13.3 \%$ |
| DPS | 130 | 130 | - | - |
| ROE (attributable to owners of the parent company) | $9.6 \%$ | $10.6 \%$ | $1.1 \% \mathrm{ppt}$ |  |

3. Forecasts by business segment

|  | 2021 Initial Forecasts | 2021 Revised Forecasts | Variance (abs) | Variance (\%) |
| :---: | :---: | :---: | :---: | :---: |
| Consolidated: revenue | 2,080.0 | 2,200.0 | +120.0 | +5.8\% |
| Japanese-domestic tobacco | 560.0 | 550.0 | -10.0 | -1.8\% |
| Core revenue | 520.0 | 510.0 | -10.0 | -1.9\% |
| International tobacco | 1,290.0 | 1,420.0 | +130.0 | +10.1\% |
| Core revenue | 1,230.0 | 1,360.0 | +130.0 | +10.6\% |
| Pharmaceutical | 76.5 | 77.0 | +0.5 | +0.7\% |
| Processed food | 151.0 | 150.0 | -1.0 | -0.7\% |
| Others | 3.0 | 3.0 | - | - |
| Consolidated: operating profit | 363.0 | 402.0 | +39.0 | +10.7\% |
| Japanese-domestic tobacco | 123.0 | 114.0 | -9.0 | -7.3\% |
| International tobacco | 280.0 | 321.0 | +41.0 | +14.6\% |
| Pharmaceutical | 7.0 | 7.0 | - | - |
| Processed food | 2.0 | 2.0 | - | - |
| Others/Elimination | -49.0 | -42.0 | +7.0 | - |
| Adjusted operating profit | 475.0 | 517.0 | +42.0 | +8.8\% |
| Japanese-domestic tobacco | 176.0 | 176.0 | - | - |
| International tobacco | 332.0 | 377.0 | +45.0 | +13.6\% |
| Pharmaceutical | 7.0 | 7.0 | - | - |
| Processed food | 3.0 | 3.0 | - | - |
| Others/Elimination | -43.0 | -46.0 | -3.0 | - |

[Reference] International tobacco business

|  | 2021 Initial <br> Forecasts | 2021 Revised <br> Forecasts | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| Core revenue | 11,900 | 12,500 | +600 | $+5.0 \%$ |
| Core revenue at constant FX | 11,850 | 12,100 | +250 | $+2.1 \%$ |
| Adjusted operating profit | 3,220 | 3,480 | +260 | $+8.1 \%$ |
| Adjusted operating profit at constant FX | 3,450 | 3,550 | +100 | $+2.9 \%$ |

## FY2021 Revised Forecasts

vs Initial Forecasts
(as of July 30, 2021)
4. Free cash flow
(Unit: JPY billion)

|  | 2021 Initial <br> Forecasts | 2021 Revised <br> Forecasts | Variance (abs) |
| :--- | ---: | ---: | ---: |
| FCF | 315.0 | 383.0 | +68.0 |

5. Capital expenditures
(Unit: JPY billion)

|  | 2021 Initial <br> Forecasts | 2021 Revised <br> Forecasts | Variance (abs) |
| :--- | ---: | ---: | ---: |
| Consolidated | 147.5 | 132.0 | -15.5 |
| Japanese-domestic tobacco | 30.0 | 28.0 | -2.0 |
| International tobacco | 92.0 | 82.0 | -10.0 |
| Pharmaceutical | 5.0 | 6.0 | +1.0 |
| Processed food | 14.5 | 14.0 | -0.5 |
| Others/Elimination | 6.0 | 2.0 | -4.0 |

6. Revised assumptions of FY2021 Forecast (vs FY2020 results)

| Japanese-domestic tobacco business | Initial Forecasts | Revised Forecasts |
| :--- | :---: | :---: |
| Total Industry volume* | a decrease of a lower 4\% range | a decrease of an upper 3\% range |
| Cigarette industry volume* | a decrease of a lower 8\% range | a decrease of a lower 9\% range |
| RRP market share in tobacco industry* | upper 20\% range | approx. 30\% |
| JT cigarette sales volume | a decrease of an upper 7\% range | a decrease of a slightly less than <br> $11 \%$ |
| JT RRP sales volume | over 4.5 BnU stick equivalent <br> $*$ |  |

* JT estimate based on shipment, annual base

| International tobacco business | Initial Forecasts | Revised Forecasts |
| :--- | :---: | :---: |
| Total shipment volume | a decrease in the mid 3\% range | almost flat |
| GFB shipment volume | a decrease of approx. $1 \%$ | an increase of approx. 3\% |

<FX assumptions>

|  | 2021 Initial <br> Forecasts | 2021 Revised <br> Forecasts | Variance (abs) | Variance (\%) |
| :--- | ---: | ---: | ---: | ---: |
| USD/JPY | 103.00 | 108.91 | +5.91 | $+5.7 \%$ |
| USD/RUB | 76.00 | 74.00 | -2.00 | $+2.7 \%$ |
| USD/GBP | 0.74 | 0.72 | -0.02 | $+2.8 \%$ |
| USD/EUR | 0.82 | 0.83 | +0.01 | $-1.2 \%$ |
| USD/CHF | 0.90 | 0.91 | +0.01 | $-1.1 \%$ |
| USD/TWD | 29.00 | 28.00 | -1.00 | $+3.6 \%$ |
| USD/TRY | 8.00 | 8.60 | +0.60 | $-7.0 \%$ |

<FX sensitivity>
FX Sensitivity Guidance for FX impact on 2021 adjusted operating profit of USD 3,480 MM based on the assumptions:
USD vs. Local currency
$1 \%$ deviation from the revised assumption rates against USD by all the currencies in the same direction (excluding JPY) leads to approximately USD 62MM impacting on USD based adjusted operating profit

This amount of approximately USD 62MM composed of:
RUB approx. 20\%, GBP approx. 15\%, TWD approx. 15\%, EUR 10\%+, TRY 5\%-, CHF just over -5\%

## USD vs. JPY

USD/JPY move of 1 yen from the assumption leads to approximately JPY 3.5 billion impact on JPY-based adjusted operating profit

## Tobacco Business Data

## International Tobacco Business

1. Summary (YTD)

In accordance with the requirements stipulated in IAS 29, the JT Group has been applying hyperinflationary accounting adjustments since Q3 2020, so the results for fiscal year 2021 on a reported basis include the impact of the adjustments. Starting from Q1 2021 results on a constant currency basis have been calculated to exclude amounts of revenue and profit that have increased due to yperinflation in certain markets.

|  | 2020 Q2 | 2021 Q2 | Variance | Variance (\%) |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
|  | Total shipment volume | 211.9 | 228.9 | +16.9 | $+8.0 \%$ |
| BNU |  |  |  |  |  |
| GFB shipment volume | 136.3 | 153.5 | +17.2 | $+12.6 \%$ | BNU |
| Core revenue | 626.1 | 736.3 | +110.2 | $+17.6 \%$ | JPY BN |
| Adjusted operating profit | 214.3 | 270.2 | +55.9 | $+26.1 \%$ | JPY BN |

[USD Reference information]

| Core revenue | 5,784 | 6,818 | +1,034 | +17.9\% | USD MM |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Adjusted operating profit | 1,980 | 2,505 | +524 | +26.5\% | USD MM |
| Constant FX basis |  |  |  |  |  |
| Core revenue | 5,784 | 6,623 | +839 | +14.5\% | USD MM |
| Adjusted operating profit | 1,980 | 2,560 | +579 | +29.2\% | USD MM |

- Contribution by cluster (vs. PY) (BNU/USD MM)

Reported basis

| $\mathbf{2 0 2 1}$ | Total shipment volume |  | GFB shipment volume |  | Core revenue |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| SWE | 36.7 | $+8.0 \%$ | 31.3 | $+10.4 \%$ | 1,214 | $+16.9 \%$ |
| NCE | 33.4 | $+12.1 \%$ | 18.4 | $+19.2 \%$ | 1,449 | $+25.3 \%$ |
| CIS+ | 62.1 | $+5.7 \%$ | 44.1 | $+10.5 \%$ | 1,511 | $+11.8 \%$ |
| RoW | 96.6 | $+8.2 \%$ | 59.7 | $+13.5 \%$ | 2,645 | $+18.2 \%$ |
| Total | 228.9 |  | 153.5 |  | 6,818 |  |

2. Total shipment volume by cluster / market (vs. PY)

| 2021 | Q1 | Q2 | Q3 | Q4 | YTD |
| :---: | :---: | :---: | :---: | :---: | :---: |
| SWE | +2.0\% | +14.5\% |  |  | +8.0\% |
| France | +16.6\% | -4.3\% |  |  | +5.3\% |
| Italy | -6.0\% | +16.4\% |  |  | +4.1\% |
| Spain | -8.8\% | +41.4\% |  |  | +12.2\% |
| NCE | +11.6\% | +12.4\% |  |  | +12.1\% |
| Germany | +13.7\% | +0.9\% |  |  | +6.9\% |
| UK | +9.4\% | +7.3\% |  |  | +8.3\% |
| CIS+ | +8.8\% | +3.1\% |  |  | +5.7\% |
| Romania | +2.2\% | +18.2\% |  |  | +10.3\% |
| Russia* | +16.5\% | -0.5\% |  |  | +6.9\% |
| RoW | +3.7\% | +12.9\% |  |  | +8.2\% |
| Iran | +3.1\% | +16.1\% |  |  | +9.3\% |
| Taiwan | +12.7\% | +1.0\% |  |  | +6.6\% |
| Turkey | +0.4\% | +26.2\% |  |  | +13.1\% |
| Total | +5.8\% | +10.1\% |  |  | +8.0\% |

*From Q1 2021 onwards, shipment volume data for Russia reflects total tobacco figures, i.e cigarettes and heated tobacco sticks. 2020 data has been adjusted accordingly.
3. GFB shipment volume by brand (vs. PY)
(BNU)

| 2021 | Q1 | Q2 | Q3 | Q4 |
| :---: | :---: | :---: | :---: | :---: |
| Winston | $\mathbf{4 1 . 2}$ | $\mathbf{4 4 . 8}$ |  | YTD |
|  | $+9.4 \%$ | $+14.5 \%$ |  | $\mathbf{8 6 . 0}$ |
| Camel | 16.0 | 18.1 |  | $+12.0 \%$ |
|  | $+11.4 \%$ | $+39.3 \%$ | $\mathbf{3 4 . 1}$ |  |
| MEVIUS | $\mathbf{4 . 0}$ | $\mathbf{4 . 0}$ | $+24.6 \%$ |  |
|  | $+1.2 \%$ | $+9.9 \%$ | $\mathbf{8 . 0}$ |  |
| LD | $\mathbf{1 2 . 4}$ | $\mathbf{1 3 . 0}$ | $+5.4 \%$ |  |
|  | $+7.9 \%$ | $-0.6 \%$ | $\mathbf{2 5 . 4}$ |  |
|  |  |  | $+3.4 \%$ |  |

## Tobacco Business Data

4. GFB shipment volume by cluster / market (vs. PY)

| 2021 | Q1 | Q2 | Q3 | Q4 | YTD |
| :---: | :---: | :---: | :---: | :---: | :---: |
| SWE | +4.8\% | +16.5\% |  |  | +10.4\% |
| France | +19.2\% | -4.7\% |  |  | +6.1\% |
| Italy | -5.3\% | +21.0\% |  |  | +6.4\% |
| Spain | -4.6\% | +42.7\% |  |  | +15.6\% |
| NCE | +18.1\% | +20.2\% |  |  | +19.2\% |
| Germany | +14.5\% | +0.9\% |  |  | +7.3\% |
| UK | -12.4\% | +0.5\% |  |  | -5.5\% |
| CIS+ | +14.1\% | +7.4\% |  |  | +10.5\% |
| Romania | +0.9\% | +14.7\% |  |  | +7.9\% |
| Russia | +29.9\% | +8.2\% |  |  | +17.6\% |
| RoW | +5.6\% | +21.9\% |  |  | +13.5\% |
| Iran | +6.8\% | +24.1\% |  |  | +15.0\% |
| Taiwan | +10.4\% | +0.5\% |  |  | +5.3\% |
| Turkey | +1.3\% | +26.5\% |  |  | +13.7\% |
| Total | +9.1\% | +16.1\% |  |  | +12.6\% |

5. Share of market by key markets

|  | 12-month moving average |  |  | 3-month average |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2020 | 2021 |  | 2020 | 2020 | 2020 | 2021 | 2021 |
|  | Jun. | Jun. | Variance | Q2 | Q3 | Q4 | Q1 | Q2 |
| France | 25.2\% | 28.4\% | +3.2\%ppt | 27.2\% | 27.6\% | 28.3\% | 28.8\% | 29.0\% |
| Italy | 24.9\% | 26.2\% | +1.3\%ppt | 25.4\% | 26.2\% | 26.0\% | 26.2\% | 26.5\% |
| Russia* | 37.2\% | 36.4\% ${ }^{*}$ | -0.8\%ppt | 36.2\% | 35.8\% | 36.7\% | 36.7\% | 36.8\% ${ }^{*}$ |
| Spain | 26.0\% | 27.4\% | +1.4\%ppt | 26.2\% | 27.0\% | 27.4\% | 27.5\% | 27.7\% |
| Taiwan | 46.5\% | 48.2\% | +1.7\%ppt | 47.5\% | 48.0\% | 48.5\% | 48.1\% | 48.1\% |
| Turkey | 26.8\% | 27.0\% | +0.3\%ppt | 26.3\% | 26.5\% | 26.8\% | 27.5\% | 27.8\%* |
| UK | 44.4\% | $45.4 \%$ | +1.1\%ppt | 44.9\% | 45.3\% | 45.3\% | 45.4\% | 45.8\%* |

Source: IRI, Nielsen, Logista, Panel Strator / Reflects the changes in historical data from the sources.
*12-month moving average and 2-month average at the end of May 2021, respectively.
**From Q1 2021 onwards, market share data for Russia reflects total tobacco figures, i.e. cigarettes and heated tobacco sticks. 2020 data has been adjusted accordingly.
6. Core revenue at constant FX by cluster (vs. PY)
(USD MM)

7. Breakdown of core revenue

In accordance with the requirements stipulated in IAS 29, the JT Group has been applying hyperinflationary accounting adjustments since Q3 2020, so the results for fiscal year 2021 on a reported basis include the impact of the adjustments. Starting from Q1 2021, results on a constant currency basis have been calculated to exclude amounts of revenue and profit that have increased due to hyperinflation in certain markets. The FX impact in the figures below include the aforementioned adjustments in addition to the prevailing FX impact

| - USD basis |  |  |  |  | (USD MM) |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q1 | Q2 | Q3 | Q4 | YTD |
| 2020 | 2,866 | 2,918 |  |  | 5,784 |
| Volume | +214 | +246 |  |  | +460 |
| Price/Mix | +187 | +192 |  |  | +379 |
| 2021 at constant | 3,268 | 3,355 |  |  | 6,623 |
| FX | +16 | +179 |  |  | +195 |
| 2021 | 3,284 | 3,535 |  |  | 6,818 |
| - JPY basis |  |  |  |  | (JPY BN) |
|  | Q1 | Q2 | Q3 | Q4 | YTD |
| 2020 | 312.0 | 314.0 |  |  | 626.1 |
| Operations | +43.7 | +47.1 |  |  | +90.8 |
| Local currencies vs. USD | +1.7 | +19.3 |  |  | +21.0 |
| JPY vs. USD | -8.5 | +6.8 |  |  | -1.6 |
| 2021 | 349.0 | 387.3 |  |  | 736.3 |

## 8. Breakdown of adjusted operating profit

In accordance with the requirements stipulated in IAS 29, the JT Group has been applying hyperinflationary accounting adjustments since Q3 2020, so the results for fiscal year 2021 on a reported basis include the impact of the adjustments. Starting from Q1 2021, results on a constant currency basis have been calculated to exclude amounts of revenue and profit that have increased due to hyperinflation in certain markets. The FX impact in the figures below include the aforementioned adjustments in addition to the prevailing FX impact.

| - USD basis |  |  |  |  | (USD MM) |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q1 | Q2 | Q3 | Q4 | YTD |
| 2020 | 956 | 1,025 |  |  | 1,980 |
| Volume | +148 | +163 |  |  | +311 |
| Price/Mix | +182 | +165 |  |  | +346 |
| Others | +22 | -101 |  |  | -79 |
| 2021 at constant | 1,308 | 1,251 |  |  | 2,560 |
| FX | -50 | -5 |  |  | -55 |
| 2021 | 1,258 | 1,247 |  |  | 2,505 |
| - JPY basis |  |  |  |  | (JPY BN) |
|  | Q1 | Q2 | Q3 | Q4 | YTD |
| 2020 | 104.1 | 110.3 |  |  | 214.3 |
| Operations | +38.4 | +24.4 |  |  | +62.8 |
| Local currencies vs. USD | -5.5 | -0.5 |  |  | -6.0 |
| JPY vs. USD | -3.3 | +2.4 |  |  | -0.9 |
| 2021 | 133.6 | 136.6 |  |  | 270.2 |
| 9. FX actual vs. PY |  |  |  |  |  |
| $\underline{2021}$ | Q1 | Q2 | Q3 | Q4 | YTD |
| USD/RUB | 74.34 | 74.22 |  |  | 74.28 |
|  | -10.8\% | -2.8\% |  |  | -6.8\% |
| USD/GBP | 0.73 | 0.72 |  |  | 0.72 |
|  | +7.8\% | +12.5\% |  |  | +10.2\% |
| USD/EUR | 0.83 | 0.83 |  |  | 0.83 |
|  | +9.4\% | +9.4\% |  |  | +9.4\% |
| USD/CHF | 0.90 | 0.91 |  |  | 0.91 |
|  | +7.1\% | +5.7\% |  |  | +6.4\% |
| USD/TWD | 28.07 | 27.99 |  |  | 28.03 |
|  | +7.3\% | +6.9\% |  |  | +7.1\% |
| USD/TRY | 7.37 | 8.37 |  |  | 7.87 |
|  | -17.2\% | -18.0\% |  |  | -17.7\% |
| USD/IRR | * | * |  |  | * |
| USD/JPY | 106.09 | 109.52 |  |  | 107.82 |
|  | -2.5\% | +1.8\% |  |  | -0.4\% |

Local currency vs USD variance: (Local currency exchange rates of same period in previous year / Local currency exchange rates of current period ) -1 JPY vs USD variance: (JPY exchange rates of current period / JPY exchange rates of same period in previous year ) -1
EUR/IRR is converted to USD/IRR in table by using cross rate.
*The closing currency rates for the month ended June 2021 have been applied when converting financial statements for subsidiaries located in hyperinflationary economies to the US dollar. Similarly, the month-end rates are also applied upon conversions from the US dollar to the Japanese yen. (USD/IRR: 217,892, USD/JPY: 110.58)

## Tobacco Business Data

## Japanese-Domestic Tobacco Business

1. Summary (YTD)

|  | 2020 Q2 | 2021 Q2 | Variance | Variance (\%) |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Cigarette industry volume (JT estimate) | 57.0 | 51.9 | -5.1 | $-8.9 \%$ | BNU |
| Cigarette sales volume | 34.2 | 30.9 | -3.3 | $-9.5 \%$ | BNU |

Excludes volumes of domestic Duty-Free, China businesses (0.9BNU in 2020 Q2 and $0.9 B N U$ in 2021 Q2, respectively) and RRP sales

| Core revenue | 248.8 | 256.4 | +7.5 | $+3.0 \%$ |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Adjusted operating profit | 81.8 | 101.3 | +19.5 | $+23.8 \%$ | JPY BN |


| 2. Cigarette sales volume |  |  | (BNU) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q1 | Q2 | Q3 | Q4 | FY |
| 2020 | 17.2 | 17.0 | 19.9 | 14.7 | 68.7 |
| 2021 | 14.9 | 16.0 |  |  |  |
| Variance | $-13.3 \%$ | $-5.7 \%$ |  |  |  |


| 3. Revenue per thousand cigarettes |  |  |  |  | (JPY) |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q1 | Q2 | Q3 | Q4 | FY |
| 2020 | 6,326 | 6,344 | 6,369 | 7,172 | 6,524 |
| 2021 | 7,155 | 7,174 |  |  |  |

Revenue per thousand cigarettes $=($ retail price sales - retailer margins - consumption tax - excise taxes $) /$ sales volume $\times 1,000$
4. Results of Reduced-Risk Products
(BNU / JPY BN)

| 2021 | Q1 | Q2 | Q3 | Q4 | YTD |
| :---: | :---: | :---: | :---: | :---: | :---: |
| RRP sales volume | 1.0 | 1.1 |  | 2.1 |  |
| RRP-related revenue | 14.7 | 14.6 |  | 29.3 |  |


| 5. Breakdown of financial results |  |  |  |  | (JPY BN) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Core revenue | Q1 | Q2 | Q3 | Q4 | YTD |
| 2020 | 125.8 | 123.0 |  |  | 248.8 |
| Cigarette volume | -14.5 | -6.2 |  |  | -20.6 |
| Cigarette price/mix | +12.3 | +13.3 |  |  | +25.6 |
| RRP/Others | +0.4 | +2.1 |  |  | +2.5 |
| 2021 | 124.1 | 132.2 |  |  | 256.4 |
| Adjusted OP | Q1 | Q2 | Q3 | Q4 | YTD |
| 2020 | 43.2 | 38.6 |  |  | 81.8 |
| Cigarette volume | -12.1 | -5.1 |  |  | -17.2 |
| Cigarette price/mix | +12.3 | +13.3 |  |  | +25.6 |
| RRP/Others | +4.5 | +6.5 |  |  | +11.0 |
| 2021 | 48.0 | 53.3 |  |  | 101.3 |

6. Cigarette market share (JT estimate)
(\%)

| JT Total | Q1 | Q2 | Q3 | Q4 | FY |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 2020 | 59.7 | 60.1 | 60.2 | 59.0 | 59.8 |
| 2021 | 59.5 | 59.5 |  |  |  |
| MEVIUS |  |  |  |  |  |
| 2020 | 28.9 | 28.8 | 28.9 | 27.4 | 28.6 |
| 2021 | 27.6 | 27.5 |  |  |  |
| Winston |  |  |  |  |  |
| 2020 | 7.3 | 7.3 | 7.3 | 7.1 | 7.2 |
| 2021 | 7.1 | 7.1 |  |  |  |
| Seven Stars |  |  |  |  |  |
| 2020 | 7.5 | 7.5 | 7.6 | 7.1 | 7.4 |
| 2021 | 7.4 | 7.3 |  |  |  |


| Natural <br> American Spirit |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
| 2020 | 2.0 | 2.0 | 1.9 | 2.1 | 2.0 |
| 2021 | 2.1 | 2.1 |  |  |  |

## Pharmaceutical Business Clinical Development as of July 30, 2021

<In-house development>

| Code (Generic Name) | Potential Indication/Dosage form |  | Mechanism | Phase (Region) | Origin | Note |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| JTE-052 <br> (delgocitinib) | Atopic dermatitis (infant) /Topical | JAKinhibitor | Suppresses overactive immune response via inhibition of Janus kinase (JAK) related to immune signal. | Phase3 (Japan) | In-house | - Co-development with Torii |
|  | Autoimmune/allergic diseases /Oral, Topical |  |  | Phase1 (Japan) |  |  |
| JTE-051 | Autoimmune/allergic diseases /Oral | Interleukin-2 inducible T cell kinase inhibitor | Suppresses overactive immune response via inhibition of the signal to activate T cells related to immune response. | Phase2(Japan) | In-house |  |
|  |  |  |  | Phase2 (Overseas) |  |  |
| JTE-451 | Autoimmune/allergic diseases /Topical | RORy antagonist | Suppresses overactive immune response via inhibition of ROR $Y$ related to Th 17 activation. | Phase1 (Japan) | In-house |  |
| JTT-251 | Type 2 diabetes mellitus /Oral | PDHK inhibitor | Decreases blood glucose by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism. | Phase1 (Overseas) | In-house |  |
| JTT-662 | Type 2 diabetes mellitus /Oral | SGLT1 inhibitor | Suppresses postprandial hyperglycemia and normalizes blood glucose level via inhibition of SGLT1. | Phase1 (Overseas) | In-house |  |
| JTE-761 | Autoimmune/allergic diseases /Oral | RORy antagonist | Suppresses overactive immune response via inhibition of ROR $Y$ related to Th 17 activation. | Phase1 (Overseas) | In-house |  |
| JTT-861 | Chronic heart failure /Oral | PDHK inhibitor | Improves cardiac function by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism. | Phase1 (Overseas) | In-house |  |

Clinical trial phase presented above is based on the first dose.
We are also conducting additional studies to examine the potential for use in additional dosage forms.
<Licensed compounds>

| Compound (JT's code) | Licensee |  | Mechanism | Note |
| :---: | :---: | :---: | :---: | :---: |
| trametinib | Novartis | MEK inhibitor | Inhibits cellular growth by specifically inhibiting the activity of MAPK/ERK pathway. |  |
| Anti-ICOS monoclonal antibody | AstraZeneca | ICOS <br> antagonist | Suppresses overactive immune response via inhibition of ICOS which regulates activation of T cells. |  |
| delgocitinib | LEO Pharma ROHTO Pharmaceutical | JAK inhibitor | Suppresses overactive immune response via inhibition of Janus kinase (JAK) related to immune signal. |  |
| enarodustat | JW Pharmaceutical Salubris | HIF-PH inhibitor | Increases red blood cells by stimulating production of erythropoietin, an erythropoiesisstimulating hormone, via inhibition of HIF-PH. |  |

Updates since the previous announcement on April 30, 2021:
-JTE-051 (Autoimmune/allergic diseases/Oral): advanced to Phase2 in Japan

- JTE-861 has entered the clinical trial stage (Phase1) in overseas.
-JTE-761 (Autoimmune/allergic diseases/Oral) : terminated
-JTE-052 : Listing on the Japanese National Health Insurance Drug Price List and Launch of CORECTIM ${ }^{\circledR}$ Ointment $0.25 \%$ in Japan

Definitions

| Terms | Definitions |
| :---: | :---: |
| Adjusted operating profit (AOP) | Adjusted operating profit (AOP) $=$ operating profit + amortization cost of acquired intangibles arising from business acquisitions + adjusted items (income and costs) * *Adjusted items (income and costs) = impairment losses on goodwill $\pm$ restructuring income and costs $\pm$ others |
| Consolidated adjusted operating profit at constant FX | The same foreign exchange rates between local currencies vs USD as well as the exchange rates between JPY and USD are applied as in the equivalent period in the previous fiscal year for international tobacco business. |
| Reduced-Risk Products (RRP) | Reduced-Risk Products are products with the potential to reduce the risks associated with smoking. |
| GFB (Global flagship brands) | GFB includes four brands namely Winston, Camel, MEVIUS and LD. |
| Total shipment volume: (International tobacco business) | Total shipment volume is the shipment volume of tobacco-based products which includes fine cut tobacco, cigars, pipe tobacco, snus, kretek and heated tobacco products but excludes contract manufactured products, waterpipe, and E-Vapor. |
| Core revenue (International tobacco business) | Core revenue includes waterpipe, and RRP, but excludes revenue from distribution, contract manufacturing and other peripheral businesses. |
| Core revenue / Adjusted operating profit at constant FX (International tobacco business) | The same foreign exchange rates between local currencies vs USD are applied as in the equivalent period in the previous fiscal year for international tobacco business. |
| Industry volume (Japanese-domestic tobacco business) | Industry volume in the Japanese market by number of sticks based on internal estimates. <br> This includes cigarettes, little cigars, RRP and others. |
| Cigarette industry volume (Japanese-domestic tobacco business) | Industry volume of ready-made cigarettes in the Japanese market by number of sticks based on the internal estimates. This includes little cigars but excludes RRP. |
| RRP industry volume (Japanese-domestic tobacco business) | Industry volume of RRP in the Japanese market by number of sticks based on the internal estimates. One pack of consumables is equivalent to 20 sticks of combustible cigarettes. This excludes RRP devices, RRP related accessories, etc. |
| Cigarette sales volume (Japanese-domestic tobacco business) | JT's cigarette sales volume excluding the volume of domestic Duty-Free and the China businesses. <br> This includes little cigars but excludes RRP. |
| RRP sales volume (Japanese-domestic tobacco business) | JT's RRP sales volume excluding the volume of domestic Duty-Free business. One pack of consumables is equivalent to 20 sticks of combustible cigarettes. This also excludes RRP devices, RRP related accessories, etc. |
| Little cigars | Products rolled in tobacco-based paper with a similar format to ready-made cigarettes and classified as "cigars" under the Tobacco Business Act of Japan. |
| Core revenue <br> (Japanese-domestic tobacco <br> Business) | Core revenue, excludes revenue from distribution of imported tobacco in the Japanese-domestic tobacco business, among others, but includes revenue from domestic Duty-free and the China businesses as well as the revenue from RRP and little cigars. |
| RRP related revenue (Japanese-domestic tobacco business) | RRP related revenue, as a part of core revenue, represents the sale of RRP including domestic Duty-Free, principally the device and the related accessories. |
| Liquidity | Cash and deposits + marketable securities + securities purchased under repurchase agreements |
| Interest-bearing debt | Short-term bank loans + CP + bonds + long-term borrowings |
| FCF | FCF is sum of cash flows from operating activities and investing activities, but excludes the following items: <br> - From operating CF: depreciation from lease transactions, interest received, dividends received, interest paid and income taxes related to these items excluding lease transactions, and other items <br> - From investing CF: purchase of investment securities (for both short-term and long-term), payments into time deposits, proceeds from sale or redemption of investment securities (for both short-term and long-term), proceeds from withdrawal of time deposits and other investing activities not for business operation purposes |

Additional definitions are provided at https://www.jt.com/media/glossary/index.html

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With approximately 58,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products ( $R R P$ ) and currently markets its heated tobacco products under its Ploom brand and various ecigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit https://www.jit.com/.

## FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements. These statements appear in a number of places in this document and include statements regarding the intent, belief, or current and future expectations of our management with respect to our business, financial condition and results of operations. In some cases, you can identify forward-looking statements by terms such as "may", "will", "should", "would", "expect", "intend", "project", "plan", "aim", "seek", "target", "anticipate", "believe", "estimate", "predict", "potential" or the negative of these terms or other similar terminology. These statements are not guarantees of future performance and are subject to various risks and uncertainties. Actual results, performance or achievements, or those of the industries in which we operate, may differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. In addition, these forward-looking statements are necessarily dependent upon assumptions, estimates and data that may be incorrect or imprecise and involve known and unknown risks and uncertainties. Forward-looking statements regarding operating results are particularly subject to a variety of assumptions, some or all of which may not be realized.

Risks, uncertainties or other factors that could cause actual results to differ materially from those expressed in any forward-looking statement include, without limitation:
(1) increase in awareness of health concerns related to smoking;
(2) regulatory developments; including, without limitation, tax increases and restrictions on sales, marketing, packaging, labeling and use of tobacco products, privately imposed restrictions and governmental investigations;
(3) litigation around the world alleging adverse health and financial effects resulting from, or relating to, tobacco products;
(4) our ability to further diversify our business beyond the traditional tobacco industry;
(5) our ability to successfully expand internationally and make investments outside Japan;
(6) competition, changing consumer preferences and behavior;
(7) our ability to manage impacts derived from business diversification or business expansion;
(8) economic, regulatory and political changes, such as nationalization, terrorism, wars and civil unrest, in countries in which we operate;
(9) fluctuations in foreign exchange rates and the costs of raw materials; and
(10) catastrophes, including natural disasters.

Contacts:
Media and Investor Relations Division
Japan Tobacco Inc.

Investors:<br>Tatsuya Tsukuura, General Manager (Tokyo)<br>E-mail: it.ir@jt.com

Ryo Ishikawa, IR Director (Geneva)
E-mail: titir@jt.com

Media:<br>Dinesh Babu Thotakura, General Manager (Tokyo)<br>E-mail: it.media.relations@jit.com


[^0]:    Investors' Meeting
    An investors' meeting (phone conference) with members of the investor community will be held on July 30, 2021 at 4:30pm Tokyo Time. An on-demand audio recording of this conference will be available on our website (https://www.it.com/investors/results/presentation financial). For detailed information on the consolidated financial results, please visit the Company's website. (https://www.jt.com/investors/).

    Note on Hyperinflationary Adjustments
    In accordance with the requirements stipulated in IAS 29, the JT Group has been applying hyperinflationary accounting adjustments since Q3 2020, so both the results and the forecasts for fiscal year 2021 on a reported basis include the impact of these adjustments. Starting from Q1 2021, both the results and forecasts on a constant currency basis have been calculated to exclude amounts of revenue and profit that have increased due to hyperinflation in certain markets.

[^1]:    ${ }^{1}$ In accordance with the requirements stipulated in IAS 29, the JT Group has been applying hyperinflationary accounting adjustments since Q3 2020, so the results for fiscal year 2021 on a reported basis include the impact of the adjustments. Starting from Q1 2021, results on a constant currency basis have been calculated to exclude amounts of revenue and profit that have increased due to hyperinflation in certain markets.
    ${ }^{2}$ Source: IRI, Logista, Nielsen, Panel Strator and JTI estimates on a 12-month rolling average and 3-month average, unless other specified, for cigarettes and fine cut (excluding snus) at the end of June 2021. Azerbaijan, Cambodia,

[^2]:    ${ }^{5}$ Source: JT estimates. Cigarette industry volume and cigarette market share include little cigars, which are classified as cigars as per the Tobacco Business Act of Japan, as well as ready-made cigarettes.
    ${ }^{6}$ Source: JT estimates industry volume of RRP in the Japanese market by number of sticks based on internal assumptions, i.e. one pack of consumables is equivalent to 20 sticks of combustible cigarettes. This excludes RRP devices, RRP- related accessories, etc.

[^3]:    ${ }^{7}$ In accordance with the requirements stipulated in IAS 29, hyperinflationary accounting adjustments have been applied to the forecasts on a reported basis since Q3 2020. The forecasts on a constant currency basis have been calculated to exclude amounts of revenue and profit that have been increased due to hyperinflation in certain markets.

[^4]:    ${ }^{8}$ Source: JT estimates. Total tobacco industry volume and cigarette industry volume include little cigars, which are classified as cigars as per the Tobacco Business Act in Japan as well as conventional cigarettes.

